CytoSorbents Expanding Marketing Reach Of CytoSorb Blood Purifier
This article was originally published in Clinica
CytoSorbents is sponsoring the REFRESH I trial of its CytoSorb extracorporeal cytokine adsorber in the US, which the company hopes will support approval of a pivotal trial of the device for reducing reduce plasma free hemoglobin and cytokines in patients undergoing complex cardiac surgery.
You may also be interested in...
Medtech Insight's Clinical Corner highlights recent R&D news and developments in ongoing clinical trials of early, late-stage and approved medical devices. This installment includes news on Abbott's Xience drug-eluting coronary stents, Xeltis' bioabsorbable devices for congenital heart defects, NeuroMetrix's Quell pain therapy, and CytoSorbents' blood purifier to treat inflammation in surgery patients.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.